<s id="wsj_0272.1"> 16
1 	 0 	 N/N 	 1 	 Inc. EG&G
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Inc. said
3 	 4 	 (S[dcl]\NP)/NP 	 1 	 it acquired
4 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 acquired said
8 	 4 	 (S[dcl]\NP)/NP 	 2 	 Berthold acquired
8 	 5 	 N/N 	 1 	 Berthold Laboratorium
8 	 6 	 N/N 	 1 	 Berthold Prof.
8 	 7 	 N/N 	 1 	 Berthold Dr.
12 	 4 	 (S[dcl]\NP)/NP 	 2 	 maker acquired
12 	 10 	 NP[nb]/N 	 1 	 maker a
12 	 11 	 N/N 	 1 	 maker German
12 	 13 	 (NP\NP)/NP 	 1 	 maker of
15 	 13 	 (NP\NP)/NP 	 2 	 instruments of
15 	 14 	 N/N 	 1 	 instruments scientific
<\s>
<s id="wsj_0272.2"> 4
0 	 1 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 Terms were
0 	 3 	 S[pss]\NP 	 1 	 Terms disclosed <XB>
1 	 2 	 (S\NP)\(S\NP) 	 2 	 were n't
3 	 1 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 disclosed were
<\s>
<s id="wsj_0272.3"> 34
3 	 1 	 (N/N)/(N/N) 	 2 	 Mass. Wellesley
5 	 0 	 NP[nb]/N 	 1 	 maker The
5 	 3 	 N/N 	 1 	 maker Mass.
5 	 6 	 (NP\NP)/NP 	 1 	 maker of
5 	 12 	 (S[dcl]\NP)/S[dcl] 	 1 	 maker said
8 	 6 	 (NP\NP)/NP 	 2 	 instruments of
8 	 7 	 N/N 	 1 	 instruments scientific
11 	 6 	 (NP\NP)/NP 	 2 	 parts of
11 	 10 	 N/N 	 1 	 parts electronic
13 	 14 	 (S[dcl]\NP)/NP 	 1 	 Berthold expects
13 	 30 	 (S[dcl]\NP)/NP 	 1 	 Berthold employs <XU>
14 	 12 	 (S[dcl]\NP)/S[dcl] 	 2 	 expects said
16 	 14 	 (S[dcl]\NP)/NP 	 2 	 sales expects
16 	 15 	 N/N 	 1 	 sales 1989
16 	 17 	 (NP\NP)/NP 	 1 	 sales of
18 	 19 	 ((N/N)/(N/N))\(S[adj]\NP) 	 3 	 more than
21 	 19 	 ((N/N)/(N/N))\(S[adj]\NP) 	 2 	 million than
21 	 20 	 (N/N)/(N/N) 	 2 	 million 100
23 	 17 	 (NP\NP)/NP 	 2 	 marks of
23 	 21 	 N/N 	 1 	 marks million
23 	 22 	 N/N 	 1 	 marks Deutsche
23 	 24 	 (NP\NP)/NP 	 1 	 marks -LRB-
25 	 24 	 (NP\NP)/NP 	 2 	 $ -LRB-
27 	 25 	 N/N[num] 	 1 	 million $
27 	 26 	 N/N 	 1 	 million 54.5
30 	 12 	 (S[dcl]\NP)/S[dcl] 	 2 	 employs said
32 	 31 	 (N/N)/(N/N) 	 2 	 400 about
33 	 30 	 (S[dcl]\NP)/NP 	 2 	 people employs
33 	 32 	 N/N 	 1 	 people 400
<\s>
<s id="wsj_0272.4"> 15
0 	 1 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 Berthold is
0 	 2 	 S[pss]\NP 	 1 	 Berthold based <XB>
0 	 11 	 (S[dcl]\NP)/NP 	 1 	 Berthold has <XU>
2 	 1 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 based is
2 	 3 	 ((S\NP)\(S\NP))/NP 	 2 	 based in
4 	 3 	 ((S\NP)\(S\NP))/NP 	 3 	 Wildbad in
7 	 3 	 ((S\NP)\(S\NP))/NP 	 3 	 Germany in
7 	 6 	 N/N 	 1 	 Germany West
11 	 10 	 (S\NP)/(S\NP) 	 2 	 has also
12 	 11 	 (S[dcl]\NP)/NP 	 2 	 operations has
12 	 13 	 (NP\NP)/NP 	 1 	 operations in
14 	 13 	 (NP\NP)/NP 	 2 	 Belgium in
<\s>
<s id="wsj_0272.5"> 40
2 	 0 	 N/N 	 1 	 Kucharski John
2 	 1 	 N/N 	 1 	 Kucharski M.
2 	 11 	 (S[dcl]\NP)/S[dcl] 	 1 	 Kucharski said
4 	 5 	 (NP[nb]/N)\NP 	 2 	 EG&G 's
6 	 5 	 (NP[nb]/N)\NP 	 1 	 chairman 's
6 	 11 	 (S[dcl]\NP)/S[dcl] 	 1 	 chairman said
9 	 5 	 (NP[nb]/N)\NP 	 1 	 executive 's
9 	 8 	 N/N 	 1 	 executive chief
9 	 11 	 (S[dcl]\NP)/S[dcl] 	 1 	 executive said
13 	 12 	 NP[nb]/N 	 1 	 acquisition the
13 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 acquisition will
13 	 15 	 (S[b]\NP)/NP 	 1 	 acquisition extend <XB>
13 	 21 	 (S[b]\NP)/NP 	 1 	 acquisition strengthen <XU>
13 	 30 	 (S[b]\NP)/NP 	 1 	 acquisition assure <XU>
14 	 11 	 (S[dcl]\NP)/S[dcl] 	 2 	 will said
15 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 extend will
16 	 17 	 (NP[nb]/N)\NP 	 2 	 EG&G 's
19 	 15 	 (S[b]\NP)/NP 	 2 	 technologies extend
19 	 17 	 (NP[nb]/N)\NP 	 1 	 technologies 's
19 	 18 	 N/N 	 1 	 technologies core
21 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 strengthen will
23 	 21 	 (S[b]\NP)/NP 	 2 	 position strengthen
23 	 22 	 NP[nb]/N 	 1 	 position its
23 	 24 	 (NP\NP)/NP 	 1 	 position in
28 	 24 	 (NP\NP)/NP 	 2 	 Community in
28 	 25 	 NP[nb]/N 	 1 	 Community the
28 	 26 	 N/N 	 1 	 Community European
28 	 27 	 N/N 	 1 	 Community Economic
30 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 assure will
32 	 30 	 (S[b]\NP)/NP 	 2 	 strength assure
32 	 31 	 NP[nb]/N 	 1 	 strength a
32 	 35 	 (NP\NP)/NP 	 1 	 strength in
34 	 30 	 (S[b]\NP)/NP 	 2 	 presence assure
34 	 31 	 NP[nb]/N 	 1 	 presence a
34 	 35 	 (NP\NP)/NP 	 1 	 presence in
39 	 35 	 (NP\NP)/NP 	 2 	 market in
39 	 36 	 NP[nb]/N 	 1 	 market the
39 	 37 	 N/N 	 1 	 market Eastern
39 	 38 	 N/N 	 1 	 market European
<\s>
<s id="wsj_0272.6"> 24
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 He said
2 	 4 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 it will
2 	 5 	 (S[b]\NP)/NP 	 1 	 it strengthen <XB>
4 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 will said
4 	 3 	 (S\NP)/(S\NP) 	 2 	 will especially
5 	 4 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 strengthen will
7 	 6 	 NP[nb]/N 	 1 	 company the
7 	 8 	 (NP[nb]/N)\NP 	 2 	 company 's
9 	 5 	 (S[b]\NP)/NP 	 2 	 efforts strengthen
9 	 8 	 (NP[nb]/N)\NP 	 1 	 efforts 's
9 	 10 	 (NP\NP)/NP 	 1 	 efforts in
9 	 20 	 (NP\NP)/NP 	 1 	 efforts in <XU>
13 	 12 	 (N/N)/(N/N) 	 2 	 growing rapidly
14 	 10 	 (NP\NP)/NP 	 2 	 field in
14 	 11 	 NP[nb]/N 	 1 	 field the
14 	 13 	 N/N 	 1 	 field growing
14 	 15 	 (NP\NP)/NP 	 1 	 field of
17 	 15 	 (NP\NP)/NP 	 2 	 instrumentation of
17 	 16 	 N/N 	 1 	 instrumentation bio-analytical
23 	 20 	 (NP\NP)/NP 	 2 	 physics in
23 	 21 	 N/N 	 1 	 physics applied
23 	 22 	 N/N 	 1 	 physics nuclear
<\s>
<s id="wsj_0272.7"> 28
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 EG&G said
3 	 0 	 S/S 	 1 	 said Separately
4 	 5 	 ((S[dcl]\NP)/PP)/NP 	 1 	 it sold
5 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 sold said
6 	 5 	 ((S[dcl]\NP)/PP)/NP 	 3 	 most sold
6 	 7 	 (NP\NP)/NP 	 1 	 most of
12 	 7 	 (NP\NP)/NP 	 2 	 subsidiary of
12 	 8 	 NP[nb]/N 	 1 	 subsidiary its
12 	 9 	 N/N 	 1 	 subsidiary Mason
12 	 10 	 N/N 	 1 	 subsidiary Research
12 	 11 	 N/N 	 1 	 subsidiary Institute
13 	 5 	 ((S[dcl]\NP)/PP)/NP 	 2 	 to sold
16 	 13 	 PP/NP 	 1 	 Inc. to
16 	 14 	 N/N 	 1 	 Inc. Transgenic
16 	 15 	 N/N 	 1 	 Inc. Sciences
20 	 19 	 (N/N)/(N/N) 	 2 	 held closely
22 	 13 	 PP/NP 	 1 	 company to
22 	 18 	 NP[nb]/N 	 1 	 company a
22 	 20 	 N/N 	 1 	 company held
22 	 21 	 N/N 	 1 	 company biotechnology
22 	 23 	 S[pss]\NP 	 1 	 company based <XB>
23 	 24 	 ((S\NP)\(S\NP))/NP 	 2 	 based in
25 	 24 	 ((S\NP)\(S\NP))/NP 	 3 	 Worcester in
27 	 24 	 ((S\NP)\(S\NP))/NP 	 3 	 Mass in
<\s>
<s id="wsj_0272.8"> 25
1 	 0 	 NP[nb]/N 	 1 	 sale The
1 	 3 	 (NP\NP)/NP 	 1 	 sale for
1 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 sale will
1 	 13 	 ((S[b]\NP)/PP)/NP 	 1 	 sale leave <XB>
4 	 3 	 (NP\NP)/NP 	 2 	 $ for
4 	 7 	 (NP\NP)/NP 	 1 	 $ in
6 	 4 	 N/N[num] 	 1 	 million $
6 	 5 	 N/N 	 1 	 million 7
8 	 7 	 (NP\NP)/NP 	 2 	 cash in
10 	 7 	 (NP\NP)/NP 	 2 	 securities in
12 	 24 	 (S[dcl]\S[dcl])\NP 	 1 	 will said
13 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 leave will
14 	 13 	 ((S[b]\NP)/PP)/NP 	 3 	 EG&G leave
15 	 13 	 ((S[b]\NP)/PP)/NP 	 2 	 with leave
18 	 17 	 (N/N)/(N/N) 	 2 	 % 12
19 	 15 	 PP/NP 	 1 	 stake with
19 	 16 	 NP[nb]/N 	 1 	 stake a
19 	 18 	 N/N 	 1 	 stake %
19 	 20 	 (NP\NP)/NP 	 1 	 stake in
21 	 20 	 (NP\NP)/NP 	 2 	 Transgenic in
23 	 24 	 (S[dcl]\S[dcl])\NP 	 2 	 executives said
<\s>
<s id="wsj_0272.9"> 20
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Mason is
1 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 is with
5 	 1 	 (S[dcl]\NP)/NP 	 2 	 lab is
5 	 2 	 NP[nb]/N 	 1 	 lab the
5 	 3 	 N/N 	 1 	 lab largest
5 	 4 	 N/N 	 1 	 lab toxicology
5 	 6 	 (NP\NP)/NP 	 1 	 lab in
8 	 6 	 (NP\NP)/NP 	 2 	 England in
8 	 7 	 N/N 	 1 	 England New
12 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 revenue with
12 	 11 	 N/N 	 1 	 revenue annual
12 	 13 	 (NP\NP)/NP 	 1 	 revenue of
14 	 13 	 (NP\NP)/NP 	 2 	 $ of
16 	 14 	 N/N[num] 	 1 	 million $
16 	 15 	 N/N 	 1 	 million 8
19 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 employees with
19 	 18 	 N/N 	 1 	 employees 140
<\s>
<s id="wsj_0272.10"> 13
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Mason serves
5 	 1 	 (S[dcl]\NP)/NP 	 2 	 customers serves
5 	 2 	 N/N 	 1 	 customers commercial
5 	 4 	 N/N 	 1 	 customers government
5 	 7 	 (NP\NP)/NP 	 1 	 customers including
10 	 7 	 (NP\NP)/NP 	 2 	 Institutes including
10 	 8 	 NP[nb]/N 	 1 	 Institutes the
10 	 9 	 N/N 	 1 	 Institutes National
10 	 11 	 (NP\NP)/NP 	 1 	 Institutes of
12 	 11 	 (NP\NP)/NP 	 2 	 Health of
<\s>
<s id="wsj_0272.11"> 22
2 	 0 	 NP[nb]/N 	 1 	 companies The
2 	 1 	 N/N 	 1 	 companies combined
2 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 companies will
2 	 4 	 (S[b]\NP)/(S[adj]\NP) 	 1 	 companies become <XB>
2 	 5 	 S[adj]\NP 	 1 	 companies profitable <XB>
3 	 10 	 (S[dcl]\S[dcl])/NP 	 1 	 will said
4 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 become will
4 	 6 	 ((S\NP)\(S\NP))/NP 	 2 	 become by
5 	 4 	 (S[b]\NP)/(S[adj]\NP) 	 2 	 profitable become
7 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 January by
7 	 8 	 N\N 	 1 	 January 1990
13 	 10 	 (S[dcl]\S[dcl])/NP 	 2 	 Sherblom said
13 	 11 	 N/N 	 1 	 Sherblom James
13 	 12 	 N/N 	 1 	 Sherblom P.
15 	 16 	 (NP[nb]/N)\NP 	 2 	 Transgenic 's
17 	 10 	 (S[dcl]\S[dcl])/NP 	 2 	 chairman said
17 	 16 	 (NP[nb]/N)\NP 	 1 	 chairman 's
21 	 10 	 (S[dcl]\S[dcl])/NP 	 2 	 officer said
21 	 16 	 (NP[nb]/N)\NP 	 1 	 officer 's
21 	 19 	 N/N 	 1 	 officer chief
21 	 20 	 N/N 	 1 	 officer executive
<\s>
